– SWITZERLAND, Zurich – Bellevue Group AG (SWX: BBN) today announced the nomination of Barbara Angehrn Pavik for her election to its Board of Directors at the next AGM on March 21, 2023. to replace Daniel Sigg who will not be standing for re-election.
“We’re very pleased that Barbara Angehrn Pavik will serve on Bellevue’s Board of Directors and further strengthen its expertise. With her many years of international experience, she can give our Group, a leading healthcare investment specialist, additional valuable inputs in the years to come,” said Board Chairman, Veit de Maddalena.
Barbara Angehrn Pavik has held several executive functions across the international healthcare industry for over 20 years, most recently as CBO and a member of the Executive Board at Vifor Pharma Group. Before the four years she spent at Vifor Pharma Group, Barbara Angehrn Pavik was the founder and CEO of Stepstone Pharma. She also held executive positions at Exelixis Pharmaceuticals International, San Francisco, Onyx Pharmaceuticals International, Zug, and Amgen International, Zug. Barbara Angehrn Pavik has been on the Board of Directors of Medmix since 2022.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.